TuHURA Biosciences (HURA) said Monday that it has completed its acquisition of Kineta.

TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.

TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.

TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.

TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.

Shares of the company were up 5% in recent Monday premarket activity.